<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="803">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769065</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-071-1001</org_study_id>
    <secondary_id>U1111-1176-7435</secondary_id>
    <nct_id>NCT02769065</nct_id>
  </id_info>
  <brief_title>Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants</brief_title>
  <official_title>A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of
      TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally
      in healthy participants and participants with mild cognitive impairment (MCI) or mild
      Alzheimer disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-071 is being tested to find a safe and well-tolerated dose in healthy participants
      (non-Japanese and Japanese) and participants with MCI or mild AD (non-Japanese).

      The study will enroll approximately 186 participants. The study consists of 4 parts:
      Single-rising dose (SRD) part (Cohorts 1-6, and 18-22), multiple-rising dose (MRD) part
      (Cohorts 7-15), Cohort 16 with 2-arm parallel design, and Cohort 17 relative bioavailability
      and food effect 3 period crossover design. Cohorts 1-12 and 18-19, will have 8 randomized
      participants, with 6 receiving TAK-071, and 2 receiving matching placebo. Cohorts 20-22 will
      have 12 randomized participants with 3 receiving TAK-071 placebo+donepezil placebo, 3
      receiving TAK-071 placebo+donepezil, and 6 receiving TAK-071+donepezil. Cohorts 13-15, will
      have 6 randomized participants, with 5 receiving TAK-071, and 1 receiving matching placebo.
      Selected cohorts (Cohorts 10 to 12) will be pretreated for 3 weeks with daily oral doses of
      donepezil (5 mg QD), followed by continued daily oral donepezil dosing during the TAK-071
      treatment period. The planned initial dose of TAK-071 for Cohort 1 is 1 mg and subsequent
      dose levels to be determined by emerging safety, tolerability, and PK data in preceding
      cohorts.

      Participants in each cohort will be randomized to receive treatment with TAK-071 or matching
      placebo using drug-in-capsule (DIC) in the morning following a minimum fast of 8 hours. In
      Cohort 16, participants will be assigned to 1 of 2 possible treatments, TAK-071 or matching
      placebo. In Cohort 17, 12 participants will be assigned to 1 of 3 treatment sequences (ABC,
      BCA, or CAB) with treatment A being Fasted State and Capsule Formulation, Treatment B being
      Fasted State and Tablet Formulation, and Treatment being C Fed State and Tablet Formulation
      (10 mg tablet formulation). In Cohorts 20-22, participants will be administered as a single
      dose of TAK-071 or placebo on Day 1, and a single dose of donepezil or placebo approximately
      24 hours later on Day 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2016</start_date>
  <completion_date type="Anticipated">March 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Experience at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Run-in Period (Day -49) up to Day 75</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose</measure>
    <time_frame>Screening (including Run-in period) up to Day 63 or Early Termination</time_frame>
    <description>The percentage of participants with any markedly abnormal standard clinical laboratory values (hematology, coagulation, serum chemistry and urinalysis) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose</measure>
    <time_frame>Screening (including Run-in period) up to Day 63 or Early Termination</time_frame>
    <description>Vital signs will include body temperature (oral), respiratory rate, supine blood pressure (after the participant has rested for at least 5 minutes) and pulse (beats per minute [bpm]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Meet the Markedly Abnormal Criteria for 12-lead ECG Parameters at Least Once Post-dose</measure>
    <time_frame>Screening up to Day 63 or Early Termination</time_frame>
    <description>Percentage of participants with any markedly abnormal values in electrocardiograms will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ: Area Under the Plasma Concentration-time Curve from Time 0 to tau Over the Dosing Interval for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on AUC (Rac[AUC] for TAK-071)</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine From Time 0 to Time t (Ae[t]) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t (f[e,t]) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CL[R]) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC12: Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 12 hours] post-dose in cohort 3 only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC36: Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 36 hours] post-dose in cohort 9 only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC12:plasma AUC12: Ratio of CSF AUC12 to the Plasma AUC12 for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 12 hours] post-dose in cohort 3 only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF AUC36:plasma AUC36: Ratio of CSF AUC36 to the Plasma AUC36 for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 36 hours] post-dose in cohort 9 only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Geometric Mean of AUC24 and Cmax</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration (Vz/F) for TAK-071</measure>
    <time_frame>Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose in each cohort</time_frame>
  </secondary_outcome>
  <number_of_arms>22</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SRD: Cohort 1: TAK-071 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 1 mg, capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 2: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 3: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 4: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on the 24-hour post-dose safety and tolerability data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 5: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 6: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 7: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules or matching placebo, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 8: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules or matching placebo, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 9: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 10: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 11: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 12: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 13: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 14: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 15: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD: Cohort 16: TAK-071 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsules, orally, once daily from Day 1 up to Day 21 followed by a 21 day washout period, followed by matching placebo capsules, orally, once daily from Day 42 up to Day 62 to healthy elderly or participants with MCI or mild AD. Dose of TAK-071 will not exceed the highest dose in MRD Cohorts 10 to 12. Donepezil 10 mg tablet orally once daily in run in period (Day -49 to Day -1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/Food Effect:Cohort 17:TAK-071 DIC 10mg+TAK-071 Tablet 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 10 mg capsule or tablet, once on Day 1 to non-Japanese healthy participants. 3-single dose regimens in a 3-way cross over design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 18: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD: Cohort 19: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD+Donepezil: Cohort 20: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD+Donepezil: Cohort 21: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability data from Cohort 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD+Donepezil: Cohort 22: TAK-071 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability data from Cohort 21 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-071</intervention_name>
    <description>TAK-071 capsules</description>
    <arm_group_label>SRD: Cohort 1: TAK-071 1 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 2: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 3: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 4: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 5: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 6: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 7: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 8: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 9: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 10: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 11: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 12: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 13: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 14: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 15: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 16: TAK-071 + Placebo</arm_group_label>
    <arm_group_label>BA/Food Effect:Cohort 17:TAK-071 DIC 10mg+TAK-071 Tablet 10mg</arm_group_label>
    <arm_group_label>SRD: Cohort 18: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 19: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 20: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 21: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 22: TAK-071 TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil over-encapsulated tablet</description>
    <arm_group_label>MRD: Cohort 10: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 11: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 12: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 16: TAK-071 + Placebo</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 20: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 21: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 22: TAK-071 TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-071 Placebo</intervention_name>
    <description>TAK-071 placebo-matching capsules</description>
    <arm_group_label>SRD: Cohort 1: TAK-071 1 mg</arm_group_label>
    <arm_group_label>SRD: Cohort 2: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 3: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 4: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 5: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 6: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 7: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 8: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 9: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 10: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 11: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 12: TAK-071 TBD + Donepezil 5 mg</arm_group_label>
    <arm_group_label>MRD: Cohort 13: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 14: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 15: TAK-071 TBD</arm_group_label>
    <arm_group_label>MRD: Cohort 16: TAK-071 + Placebo</arm_group_label>
    <arm_group_label>SRD: Cohort 18: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD: Cohort 19: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 20: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 21: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 22: TAK-071 TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-071</intervention_name>
    <description>TAK-071 tablets</description>
    <arm_group_label>BA/Food Effect:Cohort 17:TAK-071 DIC 10mg+TAK-071 Tablet 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Placebo</intervention_name>
    <description>Donepezil placebo-matching over-encapsulated tablet</description>
    <arm_group_label>SRD+Donepezil: Cohort 20: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 21: TAK-071 TBD</arm_group_label>
    <arm_group_label>SRD+Donepezil: Cohort 22: TAK-071 TBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman who weighs at least 50 kg and has a body mass index (BMI) from 18.0 to
             30.0 kg/m^2, inclusive, at Screening. Participants should be aged 18 to 55 years,
             inclusive (nonelderly at the time of informed consent and first study drug dose) for
             Cohorts 1 to 12, and 17 to 22; 20 to 55 years, inclusive, for Cohorts 13 to 15; and 55
             to 90 years, inclusive, for participants in Cohort 16.

          2. For Cohorts 13 to 15 only: First-generation Japanese, defined as having been born in
             Japan of Japanese parents and Japanese grandparents and living no more than 10 years
             outside of Japan, with no significant change in lifestyle, including diet, while
             living outside of Japan.

          3. Cohort 16 only: Healthy elderly or participants with MCI or mild AD, who must have
             Mini Mental State Examination (MMSE) score of 18 to 30, inclusive or 18 to 26
             inclusive, respectively, and no biomarker data to contradict this diagnosis.
             Participants with documented diagnosis of MCI or mild AD must be receiving ongoing
             donepezil therapy (10 mg) in the evening for a minimum of 21 days prior to Check-in
             (Day -1) or must consent to take donepezil dose titrated to at least 21 days of
             treatment with 10 mg QD prior to Check-in.

        Exclusion Criteria:

          1. Has clinically significant (Cohorts 1 to 15 and 17 to 22) or uncontrolled (Cohort 16)
             neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal
             (GI), urologic, immunologic, endocrine, or psychiatric disease or other abnormality
             (other than the disease being studied), which may impact the ability of the
             participant to participate or potentially confound the study results.

          2. Has a history of type 1 diabetes (Cohorts 1 to 22) or type 2 diabetes (Cohorts 1 to
             15, 17 to 22) or hemoglobin A1c &gt;6.5% at Screening. Note: participants with controlled
             (hemoglobin A1c &lt;7.0% at Screening) type 2 diabetes in Cohort 16 may participate in
             the study.

          3. Has a risk of suicide or suicidal ideation with intent and plan according to the
             investigator's clinical judgment (affirmative answer to questions 4 and 5 of the
             ideation section of the Columbia-Suicide Severity Rating Scale) or has made a suicide
             attempt in the previous 6 months.

          4. Cohort 16 only: Any significant neurologic disease (other than suspected incipient or
             mild AD), such as Parkinson disease, stroke, transient ischemic attack, multi-infarct
             dementia, Huntington disease, head trauma with clinically significant cognitive
             sequelae, or chronic central nervous system infection, per investigator discretion.

          5. Has current or recent (within 6 months) GI disease that would be expected to influence
             the absorption of drugs (ie, a history of malabsorption, any surgical intervention
             known to impact absorption [eg, bariatric surgery or bowel resection], esophageal
             reflux, peptic ulcer disease, erosive esophagitis, or frequent [more than once per
             week] occurrence of heartburn).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>August 2, 2017</lastchanged_date>
  <firstreceived_date>May 10, 2016</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

